CareDx Inc ((CDNA)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
CareDx Inc. is conducting the Surveillance HeartCare® Outcomes Registry, an observational study aimed at evaluating the clinical utility of HeartCare testing services in monitoring heart transplant recipients. The study focuses on assessing the effectiveness of AlloMap® and AlloSure-Heart® tests in detecting allograft rejection, offering a non-invasive alternative to traditional methods.
The intervention being tested is HeartCare, which includes AlloMap® and AlloSure-Heart®. These diagnostic tests are designed to provide comprehensive monitoring of heart transplant recipients by evaluating immune activity and graft injury, respectively.
The study is observational with a cohort model and a prospective time perspective. It involves collecting samples with DNA for analysis, focusing on the primary purpose of improving post-transplant care.
The study began on December 28, 2018, with the last update submitted on July 30, 2025. These dates mark the study’s progress and ongoing nature, indicating its active status in contributing valuable data to heart transplant care.
The update on this study could positively influence CareDx’s stock performance by reinforcing its position as a leader in transplant diagnostics. The ongoing research may enhance investor confidence, especially as the demand for non-invasive monitoring solutions grows in the healthcare industry.
The Surveillance HeartCare® Outcomes Registry is currently active, with further details available on the ClinicalTrials portal.